Labcorp strengthens oncology leadership position with the addition of personal genome diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services

Burlington, n.c.--(business wire)--labcorp (nyse: lh), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire personal genome diagnostics inc. (pgdx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. the addition of pgdx and its technology complements and accelerates labcorp's existing liquid biopsy capabilities and expands labcorp's leading oncology portfolio of next-generation seq
LH Ratings Summary
LH Quant Ranking